Cannabis extracts have been used for decades to treat medical ailments, but research into cannabinoid-based therapeutics for cancer is relatively new due to federal prohibition. In early studies, researchers have found that cannabinoids and terpenes could have strong anti-tumor effects at certain doses, which makes them a compelling target for a U.S. market that’s expected to reach $23 billion by 2020, according to ArcView Research.
In this article, we will look at CURE Pharmaceutical’s (OTCQB: CURR) collaboration with Technion and its plans to advance cannabinoid-based therapeutics targeting cancer.
Cannabinoids and Cancer
The use of cannabis extracts for medicinal purposes is well-documented throughout history, but clinical trials have been hampered by the federal government’s stance on the drug. With state and federal rules relaxed, new research has found that tetrahydrocannabinol (THC) and cannabidiol (CBD) could have anti-tumor properties at various doses by impacting the signaling taking place within the human endocannabinoid system.
Earlier this month, CURE Pharmaceutical established a pharmaceutical cannabinoid division to research and develop clinically-ready cannabinoid drug formulations and delivery systems. The company will leverage its existing infrastructure to accelerate these efforts, including its integrated drug discovery, proprietary extraction technology, genetic-specific cannabinoid research, and innovative drug development platform.
“We are well-positioned in the pharmaceutical cannabis sector and excited to work within an industry with such a promising future,” said CURE CEO Rob Davidson. “Our goal is to bring new cannabinoid molecules to market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted.”
The company’s CureFilm™ delivery technology is a flavorful dissolvable film that delivers active pharmaceutical ingredients (APIs) to patients in the most effective and convenient manner. CureFilm™ can be manufactured to dissolve at different intervals for faster absorption through the mouth or slower absorption through the gastrointestinal tract, while multiple APIs can be stored on a single strip – eliminating the need for multiple pills or medications.
Read More on CannabisFN.com
Read More